Moderna Inc. (MRNA) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Moderna Inc. (MRNA) scores 3.1 out of 10 as of , computed from its reported financial statements. That reads as low quality. The reading rests on solvency, and profitability is what holds it back.
One pillar, growth, is unscored because the filings behind it carry too little to judge. It is shown as a dash rather than a zero, and the overall score is the weighted average of what could be scored.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Moderna Inc. yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
Moderna Inc. (MRNA) has a Lemma Quality Score of 3.1 out of 10 as of October 19, 2026, which reads as low quality. A low reading means the reported numbers show weakness on several pillars at once, which is a reason to understand the business before anything else. Five pillars feed it, and every one of them is computed from what the company reported rather than from its share price.
Ranked with the 212 Healthcare companies Lemma publishes, the score sits at the 34th percentile, in the lower half of the group, above the bottom quarter. For reference, the middle of the group scores 4.4 and a company needs 6.0 to reach its top quarter, which leaves Moderna Inc. below the median.
On profitability, Moderna Inc. scores 0.2, a weak reading. Its peers have a median of 2.7 across 210 Healthcare companies, which places it well below them, at the 19th percentile. A low reading here is the first thing to explain: it is the pillar most closely tied to whether the business creates value at all.
Solvency scores 9.8 out of 10, which reads as strong. The median across 150 Healthcare companies is 6.5, so Moderna Inc. is well above its peers on this pillar and ranks at the 91st percentile. Balance sheet strength like this rarely makes headlines, but it is what lets a company keep investing when credit gets expensive.
There is no growth score for Moderna Inc.: too little of the pillar could be measured from the filings to give an honest reading. The overall is therefore the weighted average of the other pillars. Across 107 Healthcare companies the median for this pillar is 4.9. Growth needs at least three years of comparable annual statements, so a short or interrupted history leaves it blank.
Efficiency scores 1.1 out of 10, which reads as weak. The median across 200 Healthcare companies is 6.0, so Moderna Inc. is well below its peers on this pillar and ranks at the 8th percentile. Poor conversion of assets and earnings into cash can come from heavy investment phases, and it matters whether that investment is paying off.
Predictability scores 1.3 out of 10, which reads as weak. The median across 207 Healthcare companies is 3.4, so Moderna Inc. is well below its peers on this pillar and ranks at the 25th percentile. When results are this uneven, the averages behind the other pillars hide a lot of movement, and a longer history tells more than the latest year.
This is a lopsided profile. Solvency scores 9.8 but profitability only 0.2, a gap of 9.6 points, so the overall hides a business that is excellent in one respect and weak in another. A solvency lead means the balance sheet is the company’s strongest asset, a cushion that buys time when trading gets harder. A profitability shortfall is the one most worth understanding, since it bears directly on whether the business creates value.
Of everything that could lift Moderna Inc.’s score, efficiency matters most. Bringing it up to the 6.0 median of Healthcare companies would take the overall from 3.1 to roughly 4.0. Only four of the five pillars could be scored. Together they carry 80 of the 100 weight points (the full set is profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and the overall is the weighted average of those alone.
These are the Healthcare companies closest to Moderna Inc. in market value. Each has its own page scored on the same five pillars, so the comparison is like for like.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Moderna Inc. scores 3.1 out of 10, which reads as low quality. Its strongest pillar is solvency, its weakest is profitability. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Moderna Inc. ranks at the 34th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Moderna Inc.’s 3.1.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for MRNA are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card